Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$109.86 USD
-2.19 (-1.95%)
Updated Jun 10, 2024 02:54 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Jazz Pharmaceuticals PLC [JAZZ]
Reports for Purchase
Showing records 121 - 140 ( 249 total )
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
4Q18 Results; Blowout Quarter and Solid Guidance Provide Relief; But No Long Term Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
3Q18 Results; Taking Stock of and Reiterating our Neutral Thesis; M-A and Xyrem Life Cycle Remain Wildcards
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
2Q18 Results; Vyxeos Challenge a Reminder That M-A Is No Free Lunch; Reiterate Neutral but Raise to $167
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O